ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
Healthcare
$0.97 -2.12%
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
52W Low $0.40High $2.66
Volume 0.56M
Average 1.07M
Balance Sheet
Inspect the capital base behind the business.
Assets
$59.05M
FY 2025 · Annual
-60.0% YoYLiabilities
$33.06M
FY 2025 · Annual
-3.2% YoYEquity
$25.98M
FY 2025 · Annual
-77.1% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 363.67M | 48.82M | 22.41M | 17.57M | 16.37M |
| Short-term Investments | 0 | 217.39M | 160.33M | 110.19M | 28.42M |
| Net Receivables | 0 | 0 | 0 | 892K | 298K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.76M | 5.92M | 5.7M | 5.64M |
| Total Current Assets | 367.02M | 270.97M | 188.66M | 134.35M | 50.73M |
| Property, Plant & Equipment (Net) | 3.47M | 9.81M | 10.84M | 9.63M | 1.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 16.7M | 35.41M | 3.52M | 3.49M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 9.69M | 9.01M | 7.64M | 267K | 3.63M |
| Total Non-current Assets | 13.16M | 35.52M | 53.89M | 13.42M | 8.32M |
| Total Assets | 380.18M | 306.49M | 242.55M | 147.78M | 59.05M |
| Account Payables | 3.76M | 8.07M | 8.59M | 4.5M | 4.91M |
| Short-term Debt | 0 | 0 | 0 | 435K | 5.22M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.53M | 4.72M | 6.7M | 5.97M | 14.42M |
| Total Current Liabilities | 15.3M | 28.33M | 36M | 18.5M | 24.55M |
| Long-term Debt | 0 | 9.39M | 9.64M | 9.47M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.84M | 5.31M | 1.22M | 1.03M | 8.51M |
| Total Non-current Liabilities | 1.84M | 14.7M | 16.84M | 15.66M | 8.51M |
| Total Liabilities | 17.13M | 43.03M | 52.84M | 34.16M | 33.07M |
| Common Stock | 41K | 41K | 50K | 53K | 54K |
| Retained Earnings | (201.99M) | (325.47M) | (486.27M) | (621.12M) | (722.82M) |
| Accumulated OCI | (0) | (845K) | 256K | 275K | 28K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 363.05M | 263.46M | 189.71M | 113.62M | 25.98M |
| Total Debt | 742K | 10.43M | 17.2M | 16.98M | 5.22M |
| Net Debt | (362.93M) | (38.39M) | (5.21M) | (589K) | (11.16M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $32.3M |
| Short-term Investments | $108.0M |
| Other Current | $5.2M |
| Total Current Assets | $145.6M |
| PP&E (Net) | $1.1M |
| Long-term Investments | $28.8M |
| Other Non-current | $2.9M |
| Total Non-current Assets | $32.8M |
| Total Assets | $178.3M |
Analysis
Selected assets total $178.3M for Latest. The largest visible component is Short-term Investments at $108.0M, about 60.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Oct 16, 2026 | |
| 8-K | Current report | Oct 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
How much cash does ALXO have?
ALX Oncology Holdings Inc. (ALXO) reported $16.37M in cash and equivalents in fiscal 2025.
How much debt does ALXO carry?
ALX Oncology Holdings Inc. (ALXO) reported $5.22M of total debt, with net debt of -$11.16M.
Continue the stock analysis
Jump to another research area for this company.